• Scenario-Driven Best Practices for Parathyroid hormone (1-34

  2026-07-28

  This article delivers actionable, scenario-based guidance for deploying Parathyroid hormone (1-34) (human) (SKU A1129) in cell viability, proliferation, and calcium regulation workflows. Drawing on peer-reviewed evidence and real-world lab needs, it demonstrates how this PTH (1-34) peptide fragment from APExBIO provides reproducible, high-sensitivity results in bone metabolism and kidney disease research.

• Dasatinib Monohydrate (BMS-354825): Precision Kinase Inhibit

  2026-07-28

  Dasatinib Monohydrate (BMS-354825) is a multitargeted kinase inhibitor with nanomolar potency against ABL, SRC, and imatinib-resistant BCR-ABL. It is FDA-approved for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, with robust preclinical and clinical benchmarks supporting its use. The compound’s stability and solubility profile enable rigorous translational research workflows.

• Refined Jiawei-Xiaoyao Pill Formula Rapidly Reverses LPS-Ind

  2026-07-27

  This study identifies and characterizes a simplified, three-herb derivative (GMA) of the Jiawei-Xiaoyao Pill that exerts rapid antidepressant-like effects in an LPS-induced mouse model of depression. The findings reveal that GMA achieves these effects by simultaneously reducing neuroinflammation and restoring neuroplasticity signaling, with implications for optimizing herbal antidepressant therapies and mechanistic investigations in neuropsychiatric research.

• HyperScript RT SuperMix for qPCR: Precision in NAFLD Gene Ex

  2026-07-27

  Explore how HyperScript RT SuperMix for qPCR enables precise gene expression analysis in challenging models like NAFLD, offering unmatched performance for reverse transcription of complex RNA. Discover unique, evidence-driven assay strategies and practical insights.

• A40926: Dalbavancin Precursor Powering Next-Gen Antibacteria

  2026-07-26

  A40926, the natural glycopeptide antibiotic and direct precursor to dalbavancin, empowers high-sensitivity research workflows targeting Gram-positive and multidrug-resistant pathogens. This article delivers actionable protocols, troubleshooting guidance, and a translational lens on the latest biosynthetic and regulatory insights—driving reproducibility and innovation in antibiotic development.

• Endothelial SGK1 Drives Salt-Induced Vascular Stiffening

  2026-07-25

  Zhang et al. reveal that endothelial SGK1 activity is a key driver of vascular stiffening in salt-sensitive settings, acting through actin polymerization and sodium channel regulation. Their work combines genetic and pharmacological approaches—utilizing the SGK1 inhibitor EMD638683—to clarify mechanisms underlying cardiovascular risk, providing a mechanistic foundation for further translational research.

• Pomalidomide (CC-4047): Precision Tools for Myeloma Genomic

  2026-07-24

  Explore how Pomalidomide (CC-4047) enables advanced insights into mutational heterogeneity and functional assays in multiple myeloma research. Uncover application strategies and protocol optimizations grounded in recent genomic discoveries.

• High Viscosity in Tumors Drives P-gp-Mediated Chemoresistanc

  2026-07-24

  This study uncovers how elevated extracellular fluid viscosity in the tumor microenvironment induces chemoresistance by upregulating P-glycoprotein (P-gp) via mechanosensitive signaling. The findings provide mechanistic insight into tumor physical properties and suggest new experimental and therapeutic directions for overcoming drug resistance.

• Necrostatin-1: Applied RIP1 Kinase Inhibitor Workflows & Ins

  2026-07-23

  Necrostatin-1, a potent RIP1 kinase inhibitor, unlocks precise control over necroptosis in both in vitro and in vivo models—empowering researchers to dissect inflammatory and tissue injury pathways. This guide distills advanced protocols, troubleshooting strategies, and translational insights inspired by the latest studies and APExBIO’s robust compound standards.

• Berberrubine Chloride Enhances Cisplatin Sensitivity in NSCL

  2026-07-23

  A recent study demonstrates that berberrubine, an isoquinoline alkaloid and metabolite of berberine, acts as a novel thioredoxin reductase (TrxR) inhibitor, significantly enhancing cisplatin sensitivity in non-small cell lung cancer (NSCLC) models. This mechanism disrupts redox balance and DNA repair in tumor cells, providing a promising strategy for overcoming chemoresistance.

• (-)-Blebbistatin: Selective Non-Muscle Myosin II Inhibitor I

  2026-07-22

  (-)-Blebbistatin is a selective, cell-permeable non-muscle myosin II inhibitor that enables precise control of actin-myosin interactions. Its high specificity, reversibility, and robust solubility profile make it a gold standard for cytoskeletal dynamics research and cell migration studies. This article provides a mechanistic overview, protocol parameters, and evidence-based benchmarks to support advanced research applications.

• Applied Uses of EZ Cap™ Firefly Luciferase mRNA in Biolumine

  2026-07-22

  EZ Cap™ Firefly Luciferase mRNA, featuring a Cap 1 structure, unlocks robust, reproducible bioluminescent reporter assays from in vitro translation screens to in vivo imaging. This guide delivers stepwise protocols, comparative insights, and troubleshooting tips to maximize mRNA assay performance using APExBIO’s trusted reagent.

• Optimizing mRNA Delivery: EZ Cap Cy5 Firefly Luciferase mRNA

  2026-07-21

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA advances 5-moUTP modified mRNA delivery, integrating bioluminescence and fluorescence for precision research. This article uniquely deciphers assay optimization strategies and translational implications.

• DAMGO: Precision µ-Opioid Receptor Agonist for Pain Circuit

  2026-07-21

  DAMGO unlocks rigorous, circuit-level dissection of central opioid signaling—enabling research on both analgesic efficacy and side-effect mechanisms in chronic pain models. This guide details protocol enhancements, troubleshooting, and advanced applications that differentiate DAMGO from traditional opioid agonists.

• S63845: Strategic Activation of Mitochondrial Apoptosis in C

  2026-07-20

  This thought-leadership article delves into the mechanistic and translational value of S63845, a highly selective MCL1 inhibitor, for researchers confronting apoptotic resistance in hematological and solid cancers. We bridge foundational biology, recent evidence, and practical guidance to empower the next wave of translational breakthroughs.

454 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page